nodes	percent_of_prediction	percent_of_DWPC	metapath
Tranexamic Acid—PLG—Dissolution of Fibrin Clot—ANXA2—liver cancer	0.0545	0.084	CbGpPWpGaD
Tranexamic Acid—Abdominal tenderness—Sorafenib—liver cancer	0.0303	0.0864	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—EPT1—liver cancer	0.018	0.0277	CbGpPWpGaD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—IGF2—liver cancer	0.0154	0.0237	CbGpPWpGaD
Tranexamic Acid—PLG—Dissolution of Fibrin Clot—SERPINE1—liver cancer	0.0137	0.0212	CbGpPWpGaD
Tranexamic Acid—Cardiogenic shock—Epirubicin—liver cancer	0.0135	0.0385	CcSEcCtD
Tranexamic Acid—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.013	0.0371	CcSEcCtD
Tranexamic Acid—Cardiogenic shock—Doxorubicin—liver cancer	0.0125	0.0356	CcSEcCtD
Tranexamic Acid—Embolism—Sorafenib—liver cancer	0.0119	0.034	CcSEcCtD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—F2—liver cancer	0.0113	0.0173	CbGpPWpGaD
Tranexamic Acid—PLG—Blood Clotting Cascade—F2—liver cancer	0.0108	0.0167	CbGpPWpGaD
Tranexamic Acid—PLG—Complement and Coagulation Cascades—SERPINA1—liver cancer	0.0108	0.0166	CbGpPWpGaD
Tranexamic Acid—PLG—Orphan transporters—ANXA2—liver cancer	0.0103	0.0159	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—GPX3—liver cancer	0.00999	0.0154	CbGpPWpGaD
Tranexamic Acid—PLG—Orphan transporters—NR1H4—liver cancer	0.00977	0.015	CbGpPWpGaD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—MMP2—liver cancer	0.00954	0.0147	CbGpPWpGaD
Tranexamic Acid—Myocardial ischaemia—Sorafenib—liver cancer	0.00952	0.0271	CcSEcCtD
Tranexamic Acid—PLG—Blood Clotting Cascade—SERPINE1—liver cancer	0.00902	0.0139	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—ADAM17—liver cancer	0.00859	0.0132	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—SERPINA1—liver cancer	0.00844	0.013	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—HGF—liver cancer	0.00833	0.0128	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—SERPINA1—liver cancer	0.00804	0.0124	CbGpPWpGaD
Tranexamic Acid—PLG—Syndecan-4-mediated signaling events—F2—liver cancer	0.00803	0.0124	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—GPX3—liver cancer	0.00794	0.0122	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—ADAM17—liver cancer	0.00701	0.0108	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—CYCS—liver cancer	0.00691	0.0106	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—MMP2—liver cancer	0.00681	0.0105	CbGpPWpGaD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP2—liver cancer	0.00681	0.0105	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—MTHFR—liver cancer	0.0063	0.00971	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—MAPK14—liver cancer	0.0058	0.00893	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—F2—liver cancer	0.00562	0.00866	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—GGT1—liver cancer	0.00558	0.0086	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—F2—liver cancer	0.00553	0.00852	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00539	0.0083	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00539	0.0083	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—SERPINE1—liver cancer	0.00538	0.00828	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—IGF2—liver cancer	0.00527	0.00811	CbGpPWpGaD
Tranexamic Acid—Venous thrombosis—Epirubicin—liver cancer	0.00524	0.0149	CcSEcCtD
Tranexamic Acid—PLG—Folate Metabolism—MTHFR—liver cancer	0.00513	0.0079	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—MMP9—liver cancer	0.00512	0.00789	CbGpPWpGaD
Tranexamic Acid—PLG—Syndecan-4-mediated signaling events—MMP9—liver cancer	0.00512	0.00789	CbGpPWpGaD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP9—liver cancer	0.00512	0.00789	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—IGF2—liver cancer	0.00502	0.00773	CbGpPWpGaD
Tranexamic Acid—PLG—Orphan transporters—CYCS—liver cancer	0.00498	0.00767	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—HGF—liver cancer	0.00497	0.00766	CbGpPWpGaD
Tranexamic Acid—PLG—Complement and Coagulation Cascades—F2—liver cancer	0.00492	0.00758	CbGpPWpGaD
Tranexamic Acid—Venous thrombosis—Doxorubicin—liver cancer	0.00485	0.0138	CcSEcCtD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—MMP2—liver cancer	0.00477	0.00734	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—HGF—liver cancer	0.00474	0.0073	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—HBE1—liver cancer	0.00472	0.00726	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—SERPINE1—liver cancer	0.0046	0.00709	CbGpPWpGaD
Tranexamic Acid—Abdominal discomfort—Sorafenib—liver cancer	0.0046	0.0131	CcSEcCtD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—ALB—liver cancer	0.0046	0.00708	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—F2—liver cancer	0.0045	0.00693	CbGpPWpGaD
Tranexamic Acid—Embolism—Epirubicin—liver cancer	0.00441	0.0126	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—ADAMTS17—liver cancer	0.00436	0.00672	CbGpPWpGaD
Tranexamic Acid—Acute coronary syndrome—Sorafenib—liver cancer	0.00422	0.012	CcSEcCtD
Tranexamic Acid—Renal failure—Sorafenib—liver cancer	0.00421	0.012	CcSEcCtD
Tranexamic Acid—Myocardial infarction—Sorafenib—liver cancer	0.0042	0.012	CcSEcCtD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—liver cancer	0.00412	0.00634	CbGpPWpGaD
Tranexamic Acid—PLG—Complement and Coagulation Cascades—SERPINE1—liver cancer	0.0041	0.00631	CbGpPWpGaD
Tranexamic Acid—Embolism—Doxorubicin—liver cancer	0.00408	0.0116	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—MTHFR—liver cancer	0.00407	0.00627	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—TNF—liver cancer	0.00394	0.00607	CbGpPWpGaD
Tranexamic Acid—Haemoglobin—Sorafenib—liver cancer	0.00386	0.011	CcSEcCtD
Tranexamic Acid—Haemorrhage—Sorafenib—liver cancer	0.00384	0.011	CcSEcCtD
Tranexamic Acid—Ventricular arrhythmia—Epirubicin—liver cancer	0.00382	0.0109	CcSEcCtD
Tranexamic Acid—Dermatitis atopic—Epirubicin—liver cancer	0.00382	0.0109	CcSEcCtD
Tranexamic Acid—PLG—Folate Metabolism—SERPINE1—liver cancer	0.00375	0.00577	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—SERPINA1—liver cancer	0.00374	0.00577	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—ALB—liver cancer	0.00374	0.00576	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—F2—liver cancer	0.00358	0.00551	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—liver cancer	0.00357	0.0055	CbGpPWpGaD
Tranexamic Acid—Flushing—Sorafenib—liver cancer	0.00357	0.0102	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Sorafenib—liver cancer	0.00357	0.0102	CcSEcCtD
Tranexamic Acid—Dermatitis atopic—Doxorubicin—liver cancer	0.00354	0.0101	CcSEcCtD
Tranexamic Acid—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00354	0.0101	CcSEcCtD
Tranexamic Acid—PLG—Orphan transporters—PPARA—liver cancer	0.0035	0.00538	CbGpPWpGaD
Tranexamic Acid—Angiopathy—Sorafenib—liver cancer	0.00349	0.00994	CcSEcCtD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—MAPK8—liver cancer	0.00348	0.00537	CbGpPWpGaD
Tranexamic Acid—Immune system disorder—Sorafenib—liver cancer	0.00347	0.0099	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Sorafenib—liver cancer	0.00346	0.00988	CcSEcCtD
Tranexamic Acid—Arrhythmia—Sorafenib—liver cancer	0.00343	0.00979	CcSEcCtD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—liver cancer	0.0034	0.00523	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—YIF1A—liver cancer	0.00331	0.00509	CbGpPWpGaD
Tranexamic Acid—Cardiovascular disorder—Epirubicin—liver cancer	0.00322	0.00918	CcSEcCtD
Tranexamic Acid—Muscle spasms—Sorafenib—liver cancer	0.00322	0.00917	CcSEcCtD
Tranexamic Acid—PLG—Platelet degranulation—SERPINE1—liver cancer	0.00321	0.00495	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—ALB—liver cancer	0.00321	0.00494	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—IL6—liver cancer	0.00318	0.0049	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—CDH1—liver cancer	0.00312	0.00481	CbGpPWpGaD
Tranexamic Acid—SLC15A2—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.0031	0.00477	CbGpPWpGaD
Tranexamic Acid—Anaemia—Sorafenib—liver cancer	0.00309	0.00882	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00307	0.00473	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00307	0.00473	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—SERPINE1—liver cancer	0.00306	0.00471	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—ALB—liver cancer	0.00305	0.0047	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—IL2—liver cancer	0.00303	0.00467	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP2—liver cancer	0.00301	0.00463	CbGpPWpGaD
Tranexamic Acid—Cardiovascular disorder—Doxorubicin—liver cancer	0.00298	0.00849	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—SERPINE1—liver cancer	0.00298	0.00458	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—ALB—liver cancer	0.00297	0.00457	CbGpPWpGaD
Tranexamic Acid—SLC15A2—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00295	0.00455	CbGpPWpGaD
Tranexamic Acid—Loss of consciousness—Sorafenib—liver cancer	0.00294	0.00838	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—ADAM17—liver cancer	0.00294	0.00452	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—CASP3—liver cancer	0.00293	0.00451	CbGpPWpGaD
Tranexamic Acid—Atrioventricular block—Epirubicin—liver cancer	0.00292	0.00831	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—ANXA2—liver cancer	0.00291	0.00449	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—PRKCE—liver cancer	0.00288	0.00444	CbGpPWpGaD
Tranexamic Acid—Musculoskeletal pain—Epirubicin—liver cancer	0.00286	0.00816	CcSEcCtD
Tranexamic Acid—Arthralgia—Sorafenib—liver cancer	0.00285	0.00812	CcSEcCtD
Tranexamic Acid—Myalgia—Sorafenib—liver cancer	0.00285	0.00812	CcSEcCtD
Tranexamic Acid—Ventricular tachycardia—Epirubicin—liver cancer	0.00283	0.00807	CcSEcCtD
Tranexamic Acid—Pulmonary embolism—Epirubicin—liver cancer	0.00283	0.00807	CcSEcCtD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—TNF—liver cancer	0.00276	0.00425	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00276	0.00425	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—COL1A1—liver cancer	0.00275	0.00423	CbGpPWpGaD
Tranexamic Acid—Anaphylactic shock—Sorafenib—liver cancer	0.00273	0.00779	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—EXOSC2—liver cancer	0.00272	0.00419	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—TNF—liver cancer	0.00271	0.00418	CbGpPWpGaD
Tranexamic Acid—Atrioventricular block—Doxorubicin—liver cancer	0.0027	0.00769	CcSEcCtD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—MAPK8—liver cancer	0.00269	0.00415	CbGpPWpGaD
Tranexamic Acid—Nervous system disorder—Sorafenib—liver cancer	0.00268	0.00764	CcSEcCtD
Tranexamic Acid—Musculoskeletal pain—Doxorubicin—liver cancer	0.00265	0.00755	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00263	0.00405	CbGpPWpGaD
Tranexamic Acid—Pulmonary embolism—Doxorubicin—liver cancer	0.00262	0.00746	CcSEcCtD
Tranexamic Acid—Ventricular tachycardia—Doxorubicin—liver cancer	0.00262	0.00746	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00252	0.00388	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00252	0.00388	CbGpPWpGaD
Tranexamic Acid—Pulmonary oedema—Epirubicin—liver cancer	0.00252	0.00718	CcSEcCtD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—liver cancer	0.00251	0.00387	CbGpPWpGaD
Tranexamic Acid—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00249	0.00709	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PRKCE—liver cancer	0.00247	0.0038	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Sorafenib—liver cancer	0.00243	0.00694	CcSEcCtD
Tranexamic Acid—Dyspepsia—Sorafenib—liver cancer	0.0024	0.00685	CcSEcCtD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—CASP3—liver cancer	0.00239	0.00368	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00238	0.00367	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal disorder—Sorafenib—liver cancer	0.00236	0.00672	CcSEcCtD
Tranexamic Acid—Fatigue—Sorafenib—liver cancer	0.00235	0.00671	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—IGF2—liver cancer	0.00234	0.0036	CbGpPWpGaD
Tranexamic Acid—Pulmonary oedema—Doxorubicin—liver cancer	0.00233	0.00664	CcSEcCtD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP9—liver cancer	0.00226	0.00348	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal pain—Sorafenib—liver cancer	0.00223	0.00637	CcSEcCtD
Tranexamic Acid—PLG—Platelet degranulation—VEGFA—liver cancer	0.00221	0.0034	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—TNF—liver cancer	0.00221	0.0034	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—HGF—liver cancer	0.00221	0.0034	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—IL6—liver cancer	0.00219	0.00337	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—CSF2—liver cancer	0.00218	0.00336	CbGpPWpGaD
Tranexamic Acid—Abdominal pain—Sorafenib—liver cancer	0.00216	0.00615	CcSEcCtD
Tranexamic Acid—Anaphylactoid reaction—Epirubicin—liver cancer	0.00212	0.00605	CcSEcCtD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—VEGFA—liver cancer	0.0021	0.00324	CbGpPWpGaD
Tranexamic Acid—Cerebrovascular accident—Epirubicin—liver cancer	0.00209	0.00597	CcSEcCtD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—AKT1—liver cancer	0.00205	0.00316	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—TGFB1—liver cancer	0.00203	0.00312	CbGpPWpGaD
Tranexamic Acid—Migraine—Epirubicin—liver cancer	0.00202	0.00576	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Sorafenib—liver cancer	0.00201	0.00574	CcSEcCtD
Tranexamic Acid—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00196	0.0056	CcSEcCtD
Tranexamic Acid—Asthenia—Sorafenib—liver cancer	0.00196	0.00559	CcSEcCtD
Tranexamic Acid—PLG—Folate Metabolism—TP53—liver cancer	0.00195	0.003	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—PIK3CA—liver cancer	0.00194	0.00299	CbGpPWpGaD
Tranexamic Acid—Cerebrovascular accident—Doxorubicin—liver cancer	0.00194	0.00553	CcSEcCtD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—TGFB1—liver cancer	0.00193	0.00297	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—SERPINA1—liver cancer	0.00193	0.00297	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CHN2—liver cancer	0.00188	0.0029	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—TP53—liver cancer	0.00188	0.00289	CbGpPWpGaD
Tranexamic Acid—Migraine—Doxorubicin—liver cancer	0.00187	0.00533	CcSEcCtD
Tranexamic Acid—Diarrhoea—Sorafenib—liver cancer	0.00187	0.00533	CcSEcCtD
Tranexamic Acid—Dizziness—Sorafenib—liver cancer	0.00181	0.00515	CcSEcCtD
Tranexamic Acid—PLG—Folate Metabolism—IL6—liver cancer	0.00178	0.00274	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—MAPK14—liver cancer	0.00177	0.00272	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—TNF—liver cancer	0.00175	0.0027	CbGpPWpGaD
Tranexamic Acid—Vomiting—Sorafenib—liver cancer	0.00174	0.00495	CcSEcCtD
Tranexamic Acid—Angina pectoris—Epirubicin—liver cancer	0.00173	0.00493	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—IFT88—liver cancer	0.00172	0.00265	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—F2—liver cancer	0.00171	0.00264	CbGpPWpGaD
Tranexamic Acid—Headache—Sorafenib—liver cancer	0.00171	0.00488	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—PIK3CD—liver cancer	0.00168	0.00259	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	0.00164	0.00252	CbGpPWpGaD
Tranexamic Acid—Nausea—Sorafenib—liver cancer	0.00162	0.00462	CcSEcCtD
Tranexamic Acid—Angina pectoris—Doxorubicin—liver cancer	0.0016	0.00456	CcSEcCtD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—AKT1—liver cancer	0.00159	0.00244	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00157	0.00242	CbGpPWpGaD
Tranexamic Acid—Renal failure—Epirubicin—liver cancer	0.00156	0.00443	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—KDR—liver cancer	0.00154	0.00238	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—ATF3—liver cancer	0.00153	0.00235	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—RAF1—liver cancer	0.0015	0.00231	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.0015	0.00231	CbGpPWpGaD
Tranexamic Acid—Sinusitis—Epirubicin—liver cancer	0.00148	0.00423	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—PIK3CB—liver cancer	0.00147	0.00226	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—MTOR—liver cancer	0.00147	0.00226	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	0.00144	0.00222	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00144	0.00222	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00144	0.00222	CbGpPWpGaD
Tranexamic Acid—Renal failure—Doxorubicin—liver cancer	0.00144	0.0041	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—IFNA1—liver cancer	0.00144	0.00221	CbGpPWpGaD
Tranexamic Acid—Haemoglobin—Epirubicin—liver cancer	0.00143	0.00407	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	0.00142	0.00219	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—ALB—liver cancer	0.00142	0.00219	CbGpPWpGaD
Tranexamic Acid—Haemorrhage—Epirubicin—liver cancer	0.00142	0.00405	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—IL6—liver cancer	0.00142	0.00218	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—CDKN1B—liver cancer	0.00138	0.00212	CbGpPWpGaD
Tranexamic Acid—Sinusitis—Doxorubicin—liver cancer	0.00137	0.00392	CcSEcCtD
Tranexamic Acid—Visual impairment—Epirubicin—liver cancer	0.00137	0.0039	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00136	0.0021	CbGpPWpGaD
Tranexamic Acid—Eye disorder—Epirubicin—liver cancer	0.00133	0.00378	CcSEcCtD
Tranexamic Acid—Haemoglobin—Doxorubicin—liver cancer	0.00132	0.00377	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Epirubicin—liver cancer	0.00132	0.00376	CcSEcCtD
Tranexamic Acid—Flushing—Epirubicin—liver cancer	0.00132	0.00376	CcSEcCtD
Tranexamic Acid—Haemorrhage—Doxorubicin—liver cancer	0.00131	0.00375	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—CDH1—liver cancer	0.00131	0.00201	CbGpPWpGaD
Tranexamic Acid—Angiopathy—Epirubicin—liver cancer	0.00129	0.00367	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—RAF1—liver cancer	0.00129	0.00198	CbGpPWpGaD
Tranexamic Acid—Immune system disorder—Epirubicin—liver cancer	0.00128	0.00366	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Epirubicin—liver cancer	0.00128	0.00365	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—PRKCE—liver cancer	0.00127	0.00196	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—CDKN1A—liver cancer	0.00127	0.00196	CbGpPWpGaD
Tranexamic Acid—Arrhythmia—Epirubicin—liver cancer	0.00127	0.00362	CcSEcCtD
Tranexamic Acid—Visual impairment—Doxorubicin—liver cancer	0.00127	0.00361	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP2—liver cancer	0.00126	0.00194	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	0.00126	0.00193	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—SERPINE1—liver cancer	0.00124	0.0019	CbGpPWpGaD
Tranexamic Acid—Eye disorder—Doxorubicin—liver cancer	0.00123	0.0035	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Doxorubicin—liver cancer	0.00122	0.00348	CcSEcCtD
Tranexamic Acid—Flushing—Doxorubicin—liver cancer	0.00122	0.00348	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—CYCS—liver cancer	0.00122	0.00187	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—ABL1—liver cancer	0.00121	0.00186	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—IGF2—liver cancer	0.0012	0.00185	CbGpPWpGaD
Tranexamic Acid—Back pain—Epirubicin—liver cancer	0.0012	0.00341	CcSEcCtD
Tranexamic Acid—Angiopathy—Doxorubicin—liver cancer	0.00119	0.0034	CcSEcCtD
Tranexamic Acid—Muscle spasms—Epirubicin—liver cancer	0.00119	0.00339	CcSEcCtD
Tranexamic Acid—Immune system disorder—Doxorubicin—liver cancer	0.00119	0.00338	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Doxorubicin—liver cancer	0.00118	0.00338	CcSEcCtD
Tranexamic Acid—Arrhythmia—Doxorubicin—liver cancer	0.00117	0.00335	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—IL2—liver cancer	0.00115	0.00178	CbGpPWpGaD
Tranexamic Acid—Ill-defined disorder—Epirubicin—liver cancer	0.00115	0.00327	CcSEcCtD
Tranexamic Acid—Anaemia—Epirubicin—liver cancer	0.00114	0.00326	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—HGF—liver cancer	0.00114	0.00175	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—STAT3—liver cancer	0.00113	0.00175	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—CSF2—liver cancer	0.00112	0.00173	CbGpPWpGaD
Tranexamic Acid—Malaise—Epirubicin—liver cancer	0.00111	0.00318	CcSEcCtD
Tranexamic Acid—Back pain—Doxorubicin—liver cancer	0.00111	0.00316	CcSEcCtD
Tranexamic Acid—Muscle spasms—Doxorubicin—liver cancer	0.0011	0.00314	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Epirubicin—liver cancer	0.00109	0.0031	CcSEcCtD
Tranexamic Acid—Convulsion—Epirubicin—liver cancer	0.00107	0.00305	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Doxorubicin—liver cancer	0.00106	0.00303	CcSEcCtD
Tranexamic Acid—Anaemia—Doxorubicin—liver cancer	0.00106	0.00302	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00106	0.00163	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—SHC3—liver cancer	0.00105	0.00162	CbGpPWpGaD
Tranexamic Acid—Arthralgia—Epirubicin—liver cancer	0.00105	0.003	CcSEcCtD
Tranexamic Acid—Myalgia—Epirubicin—liver cancer	0.00105	0.003	CcSEcCtD
Tranexamic Acid—Chest pain—Epirubicin—liver cancer	0.00105	0.003	CcSEcCtD
Tranexamic Acid—Discomfort—Epirubicin—liver cancer	0.00104	0.00297	CcSEcCtD
Tranexamic Acid—Malaise—Doxorubicin—liver cancer	0.00103	0.00294	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Epirubicin—liver cancer	0.00101	0.00288	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Doxorubicin—liver cancer	0.00101	0.00287	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—CASP3—liver cancer	0.001	0.00154	CbGpPWpGaD
Tranexamic Acid—Convulsion—Doxorubicin—liver cancer	0.000991	0.00283	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Epirubicin—liver cancer	0.00099	0.00282	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—VEGFA—liver cancer	0.00098	0.00151	CbGpPWpGaD
Tranexamic Acid—Myalgia—Doxorubicin—liver cancer	0.000974	0.00278	CcSEcCtD
Tranexamic Acid—Chest pain—Doxorubicin—liver cancer	0.000974	0.00278	CcSEcCtD
Tranexamic Acid—Arthralgia—Doxorubicin—liver cancer	0.000974	0.00278	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—KRAS—liver cancer	0.000973	0.0015	CbGpPWpGaD
Tranexamic Acid—Discomfort—Doxorubicin—liver cancer	0.000962	0.00274	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—IGF2—liver cancer	0.000947	0.00146	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP9—liver cancer	0.000947	0.00146	CbGpPWpGaD
Tranexamic Acid—Hypotension—Epirubicin—liver cancer	0.000943	0.00269	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Doxorubicin—liver cancer	0.000934	0.00266	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000919	0.00262	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Doxorubicin—liver cancer	0.000916	0.00261	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—MAPK14—liver cancer	0.000911	0.0014	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Epirubicin—liver cancer	0.0009	0.00257	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—TGFB1—liver cancer	0.000899	0.00139	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—PIK3CA—liver cancer	0.000894	0.00138	CbGpPWpGaD
Tranexamic Acid—Dyspepsia—Epirubicin—liver cancer	0.000888	0.00253	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—F2—liver cancer	0.000883	0.00136	CbGpPWpGaD
Tranexamic Acid—Hypotension—Doxorubicin—liver cancer	0.000872	0.00249	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Epirubicin—liver cancer	0.000871	0.00248	CcSEcCtD
Tranexamic Acid—Fatigue—Epirubicin—liver cancer	0.00087	0.00248	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—PPARA—liver cancer	0.000854	0.00131	CbGpPWpGaD
Tranexamic Acid—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000851	0.00243	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—PIK3CG—liver cancer	0.000845	0.0013	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Doxorubicin—liver cancer	0.000832	0.00237	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Epirubicin—liver cancer	0.000831	0.00237	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—HRAS—liver cancer	0.000827	0.00127	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal pain—Epirubicin—liver cancer	0.000825	0.00235	CcSEcCtD
Tranexamic Acid—Dyspepsia—Doxorubicin—liver cancer	0.000822	0.00234	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—FST—liver cancer	0.000818	0.00126	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000806	0.0023	CcSEcCtD
Tranexamic Acid—Fatigue—Doxorubicin—liver cancer	0.000805	0.0023	CcSEcCtD
Tranexamic Acid—Abdominal pain—Epirubicin—liver cancer	0.000798	0.00227	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—IL6—liver cancer	0.000792	0.00122	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TRIO—liver cancer	0.000781	0.0012	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—TGFB1—liver cancer	0.00078	0.0012	CbGpPWpGaD
Tranexamic Acid—Feeling abnormal—Doxorubicin—liver cancer	0.000769	0.00219	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	0.000765	0.00118	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal pain—Doxorubicin—liver cancer	0.000763	0.00218	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—CCR4—liver cancer	0.000749	0.00115	CbGpPWpGaD
Tranexamic Acid—Hypersensitivity—Epirubicin—liver cancer	0.000743	0.00212	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—PIK3CD—liver cancer	0.000742	0.00114	CbGpPWpGaD
Tranexamic Acid—Abdominal pain—Doxorubicin—liver cancer	0.000738	0.0021	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—SERPINE1—liver cancer	0.000734	0.00113	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—ALB—liver cancer	0.000733	0.00113	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—AKT1—liver cancer	0.00073	0.00112	CbGpPWpGaD
Tranexamic Acid—Asthenia—Epirubicin—liver cancer	0.000724	0.00206	CcSEcCtD
Tranexamic Acid—SLC15A2—SLC-mediated transmembrane transport—ALB—liver cancer	0.000713	0.0011	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—F2—liver cancer	0.000694	0.00107	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000694	0.00107	CbGpPWpGaD
Tranexamic Acid—Diarrhoea—Epirubicin—liver cancer	0.00069	0.00197	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Doxorubicin—liver cancer	0.000688	0.00196	CcSEcCtD
Tranexamic Acid—Asthenia—Doxorubicin—liver cancer	0.00067	0.00191	CcSEcCtD
Tranexamic Acid—Dizziness—Epirubicin—liver cancer	0.000667	0.0019	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—RAF1—liver cancer	0.000663	0.00102	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—PIK3CB—liver cancer	0.000647	0.000997	CbGpPWpGaD
Tranexamic Acid—Vomiting—Epirubicin—liver cancer	0.000642	0.00183	CcSEcCtD
Tranexamic Acid—Diarrhoea—Doxorubicin—liver cancer	0.000639	0.00182	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ALB—liver cancer	0.000634	0.000977	CbGpPWpGaD
Tranexamic Acid—Headache—Epirubicin—liver cancer	0.000632	0.0018	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—AKT1—liver cancer	0.000625	0.000963	CbGpPWpGaD
Tranexamic Acid—Dizziness—Doxorubicin—liver cancer	0.000617	0.00176	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000603	0.000929	CbGpPWpGaD
Tranexamic Acid—Nausea—Epirubicin—liver cancer	0.000599	0.00171	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—IL2—liver cancer	0.000594	0.000915	CbGpPWpGaD
Tranexamic Acid—Vomiting—Doxorubicin—liver cancer	0.000594	0.00169	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—ADAM17—liver cancer	0.000592	0.000911	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—MMP2—liver cancer	0.000589	0.000907	CbGpPWpGaD
Tranexamic Acid—Headache—Doxorubicin—liver cancer	0.000585	0.00167	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—RAF1—liver cancer	0.000574	0.000884	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PSMD10—liver cancer	0.000556	0.000857	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PSMA4—liver cancer	0.000556	0.000857	CbGpPWpGaD
Tranexamic Acid—Nausea—Doxorubicin—liver cancer	0.000555	0.00158	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—VEGFA—liver cancer	0.000505	0.000778	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—PPARA—liver cancer	0.000487	0.00075	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—TGFB1—liver cancer	0.000464	0.000714	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—CTNNB1—liver cancer	0.000451	0.000695	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PRKCE—liver cancer	0.000431	0.000664	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—KRAS—liver cancer	0.000429	0.000661	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—IGF2—liver cancer	0.000408	0.000629	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—PIK3CA—liver cancer	0.000395	0.000608	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—TP53—liver cancer	0.000382	0.000588	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CSF2—liver cancer	0.000381	0.000587	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—H2AFX—liver cancer	0.000376	0.000579	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—HRAS—liver cancer	0.000365	0.000562	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ALB—liver cancer	0.000362	0.000558	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TERT—liver cancer	0.00034	0.000523	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—RAF1—liver cancer	0.000328	0.000504	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—AKT1—liver cancer	0.000322	0.000496	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—KDR—liver cancer	0.000311	0.000479	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MAPK14—liver cancer	0.000309	0.000476	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—ESR1—liver cancer	0.000303	0.000466	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—F2—liver cancer	0.000299	0.000461	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PIK3CG—liver cancer	0.000286	0.000441	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—APC—liver cancer	0.000286	0.000441	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—BRAF—liver cancer	0.000269	0.000414	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PIK3CD—liver cancer	0.000252	0.000388	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—SERPINE1—liver cancer	0.000249	0.000383	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—RAF1—liver cancer	0.000225	0.000346	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PIK3CB—liver cancer	0.000219	0.000338	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MTOR—liver cancer	0.000219	0.000338	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CDKN1B—liver cancer	0.000206	0.000317	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CASP3—liver cancer	0.000202	0.000311	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—IL2—liver cancer	0.000201	0.00031	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CCND1—liver cancer	0.000196	0.000302	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—JUN—liver cancer	0.000196	0.000302	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CTNNB1—liver cancer	0.000195	0.0003	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MMP9—liver cancer	0.000191	0.000294	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CDKN1A—liver cancer	0.00019	0.000293	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MAPK8—liver cancer	0.000185	0.000286	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—VEGFA—liver cancer	0.000171	0.000264	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—STAT3—liver cancer	0.00017	0.000261	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MYC—liver cancer	0.000158	0.000243	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TGFB1—liver cancer	0.000157	0.000242	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—KRAS—liver cancer	0.000146	0.000224	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PIK3CA—liver cancer	0.000134	0.000206	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TP53—liver cancer	0.000129	0.000199	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—HRAS—liver cancer	0.000124	0.000191	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—IL6—liver cancer	0.000118	0.000182	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—AKT1—liver cancer	0.000109	0.000168	CbGpPWpGaD
